Iridium(<scp>iii</scp>)–Cp*-(imidazo[4,5-<i>f</i>][1,10]phenanthrolin-2-yl)phenol analogues as hypoxia active, GSH-resistant cancer cytoselective and mitochondria-targeting cancer stem cell therapeutic agents-Reference-Cited by-同舟云学术

Iridium(iii)–Cp*-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol analogues as hypoxia active, GSH-resistant cancer cytoselective and mitochondria-targeting cancer stem cell therapeutic agents

Published:2022 Issue:14 Volume:51 Page:5494-5514
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Kar Binoy¹^ORCID,Shanavas Shanooja²^ORCID,Nagendra Apoorva H.²,Das Utpal¹^ORCID,Roy Nilmadhab¹^ORCID,Pete Sudhindra¹^ORCID,Sharma S Ajay¹^ORCID,De Sourav¹^ORCID,Kumar S K Ashok¹^ORCID,Vardhan Seshu³^ORCID,Sahoo Suban K.³^ORCID,Panda Debashis⁴^ORCID,Shenoy Sudheer²^ORCID,Bose Bipasha²^ORCID,Paira Priyankar¹^ORCID

Affiliation:

1. Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamilnadu, India

2. Department Stem Cells and Regenerative Medicine Centre, Institution Yenepoya Research Centre, Yenepoya University, University Road, Derlakatte, Mangalore 575018, Karnataka, India

3. Department of Applied Chemistry, S. V. National Institute of Technology (SVNIT), Ichchanath, Surat, Gujrat-395007, India

4. Department of Basic Sciences and Humanities, Rajiv Gandhi Institute of Petroleum Technology, An Institution of National Importance, Jais, Amethi-229304, Uttar Pradesh, India

Abstract

GSH-resistant, hypoxia active iridium(iii)–Cp*-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes were developed as highly cytoselective anticancer agents and mitochondria-targeting CSC therapeutic agents.

Funder

Department of Science and Technology, Ministry of Science and Technology, India

VIT University

Science and Engineering Research Board

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/DT/D2DT00168C

Reference67 articles.

1. Assessment of the Evolution of Cancer Treatment Therapies